SCHEMBL19668407

SCHEMBL19668407

O=C(O)c1cn(C2CC2)c2cc(N3CCN(C(=O)c4ccc(CC(P(=O)(O)O)P(=O)(O)O)cc4)CC3)c(F)cc2c1=O

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PIK3CG P48736 7/20 0.63
▸ KDM4E B2RXH2 4/20 0.62
▸ ALDH1A1 P00352 4/20 0.62
▸ PIK3CD O00329 5/20 0.60
▸ PIK3R1 P27986 5/20 0.60
▸ PIK3CA P42336 5/20 0.60
▸ LMNA P02545 3/20 0.59
▸ HPGD P15428 2/20 0.59
▸ HSD17B10 Q99714 2/20 0.59
▸ MAPT P10636 1/20 0.59
▸ CYP1A2 P05177 1/20 0.57
▸ TOP2A P11388 1/20 0.57
▸ CYP2C9 P11712 1/20 0.57
▸ TOP2B Q02880 1/20 0.57
▸ HRH3 Q9Y5N1 1/20 0.52
▸ HTT P42858 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19668398 0.90 PIK3CG (0.62) PIK3CGKDM4EALDH1A1PIK3CDPIK3R1
SCHEMBL19668798 0.89 KDM4E (0.61) PIK3CGKDM4EALDH1A1PIK3CDPIK3R1
SCHEMBL19668721 0.89 KDM4E (0.60) PIK3CGKDM4EALDH1A1PIK3CDPIK3R1
SCHEMBL19668425 0.88 KDM4E (0.59) PIK3CGKDM4EALDH1A1PIK3CDPIK3R1
SCHEMBL19668698 0.87 KDM4E (0.58) PIK3CGKDM4EALDH1A1PIK3CDPIK3R1
SCHEMBL19668722 0.86 KDM4E (0.57) PIK3CGKDM4EALDH1A1PIK3CDPIK3R1
SCHEMBL26931897 0.85 KDM4E (0.59) PIK3CGKDM4EALDH1A1PIK3CDPIK3R1
SCHEMBL10810239 0.85 KDM4E (0.75) PIK3CGKDM4EALDH1A1PIK3CDPIK3R1
SCHEMBL14010122 0.84 KDM4E (0.69) PIK3CGKDM4EALDH1A1PIK3CDPIK3R1
SCHEMBL14010130 0.84 CA1 (0.56) PIK3CGKDM4EALDH1A1PIK3CDPIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624057-B2 Bisphosphonate quinolone conjugates and uses thereof BIOVINC, LLC (US) 2026-05-12 — — US disclosed
US-20240182504-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF BIOVINC LLC (US) 2024-06-06 — — US disclosed
US-11840549-B2 Bisphosphonate quinolone conjugates and uses thereof BIOVINC, LLC (US) 2023-12-12 — — US disclosed
US-11840549-B2 Bisphosphonate quinolone conjugates and uses thereof BIOVINC, LLC (US) 2023-12-12 — — US disclosed
US-11840549-B2 Bisphosphonate quinolone conjugates and uses thereof BIOVINC, LLC (US) 2023-12-12 — — US disclosed
US-20210101920-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-04-08 — — US disclosed
US-20210101920-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-04-08 — — US disclosed
US-10865220-B2 Bisphosphonate quinolone conjugates and uses thereof BIOVINC, LLC (US) 2020-12-15 — — US disclosed
US-10865220-B2 Bisphosphonate quinolone conjugates and uses thereof BIOVINC, LLC (US) 2020-12-15 — — US disclosed
US-20190169214-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF BIOVINC LLC (US) 2019-06-06 — — US disclosed
US-20190169214-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF BIOVINC LLC (US) 2019-06-06 — — US disclosed
EP-3464307-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF Biovinc, LLC. (US) 2019-04-10 — — EP disclosed
WO-2017210611-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF BIOVINC, LLC. (US) 2017-12-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10865220-B2 Bisphosphonate quinolone conjugates and uses thereof BPGM, PHPT1, NQO2 PIK3CG 191/4885KDM4E 3437/4885ALDH1A1 2346/4885
US-20190169214-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF BPGM, PHPT1, NQO2 PIK3CG 191/4885KDM4E 3437/4885ALDH1A1 2346/4885
US-20240182504-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF BPGM, PHPT1, NQO2 PIK3CG 191/4885KDM4E 3437/4885ALDH1A1 2346/4885
US-11840549-B2 Bisphosphonate quinolone conjugates and uses thereof BPGM, PHPT1, NQO2 PIK3CG 191/4885KDM4E 3437/4885ALDH1A1 2346/4885
US-12624057-B2 Bisphosphonate quinolone conjugates and uses thereof PTMS, CYP24A1, PHPT1 PIK3CG 772/4885KDM4E 476/4885ALDH1A1 4057/4885
US-20210101920-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF BPGM, PHPT1, NQO2 PIK3CG 191/4885KDM4E 3437/4885ALDH1A1 2346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback